Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001209191-23-059908

President and CEO sold 12,000 shares at $14.64 ($175,709)

  • President and CEO acquired 12,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Kintz Samuel · President and CEO

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2023-12-26 Exercise or conversion : show line 1 in the form 10b5-1 +12,000 $1.12 $13,440 12,000 D
2023-12-26 Sale : show line 2 in the form 10b5-1 −12,000 $14.64 $175,709 0 D
Open-market sales · 12,000 sh · avg $14.64 · $175,709

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2023-12-26 Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (right to buy) −12,000 296,550 D
Loading xslF345X05/doc4.xml…